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In Epstein–Barr virus (EBV)-infected BL cells, the oncogenic EBV-encoded nuclear antigen 1 (EBNA 1) gene is directed from
the latent promoter Qp. Yeast one-hybrid screen analysis using the 250 to 237 sequence of Qp as the bait was carried out
to identify transcriptional factors that may control Qp activity. Results showed that Smad4 binds the 250 to 237 sequence
of Qp, indicating that this promoter is potentially regulated by TGF-b. The association of Smad4 with Qp was further
confirmed by supershift of EMSA complexes using Smad4-specific antibody. The transfection of a Qp reporter construct in
two EBV(1) BL cell lines, Rael and WW2, showed that Qp activity is repressed in response to the TGF-b treatment. This
repression involves the interaction of a Smad3/Smad4 complex and the transcriptional repressor TGIF, as determined by
cotransfection assay and coimmunoprecipitation analysis. Results suggest that TGF-b may transcriptionally repress Qp
through the Smad4-binding site in human BL cells. © 2000 Academic Press
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Epstein–Barr virus (EBV) is a herpesvirus associated
with many malignant diseases, including Africa Bur-
kitt’s lymphoma (BL), nasopharyngeal carcinoma
(NPC), Hodgkin’s disease, and T-cell lymphoma (Rick-
inson and Kieff, 1996). In these infected tumor cells,
the expression of EBV latent genes is limited. For
example, EBNA 1 is the only antigen expressed in BL
cells (Rowe et al., 1986). Transgenic mice specifically
expressing EBNA 1 in B cells show B-cell neoplasia
(Wilson et al., 1996) and overexpression of EBNA 1
nhances the malignant progression of human NPC
ells, indicating an important role of EBNA 1 in EBV-
ssociated malignancies (Sheu et al., 1996). EBNA 1 is
DNA-binding protein that binds to the ori-P region of
he EBV genome and allows the viral genome to be
resent as an episome in infected cells (Yates et al.,
985). Transcription of the EBNA 1 gene in BL and NPC
ells is initiated from a latent promoter, Qp (Tsai et al.,
995). Several studies show that Qp expression can be
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184egulated by interferon regulatory factors (IRFs)
hrough interaction with the basal transcription ma-
hinery (Nonkwelo et al., 1995, 1997) and Qp is posi-
ively regulated by JAK/STAT activation through two
otential STAT-binding sites (Chen et al., 1999), indi-
ating that Qp is potentially regulated by cytokines. Xu
t al. (1999, 2000) also reported that the levels of
GF-b in serum samples from patients with EBV-asso-
ciated BL and NPC are elevated compared to those
from healthy individuals. TGF-b is a cytokine that plays
mportant regulatory roles in cell growth, morphogen-
sis, cell differentiation, and apoptosis (Massague,
998).
Following TGF-b stimulation, the constitutively ac-
tive type II receptor kinase (TbRII) phosphorylates and
ctivates the kinase TbRI and its downstream signal-
ing mediators, or Smads. Activated Smad2/Smad3
forms a heteromeric complex with Smad4 and is then
translocated into the nucleus to affect the transcrip-
tional activity of target genes (Zhang et al., 1997).
mad complexes participate in transactivation by as-
ociation with a coactivator, the p300/CREB-binding
rotein, through the interaction between Smad3 and
he C-terminal fragment of p300 in a temporal and
hosphorylation-dependent manner (Feng et al., 1998).
n the other hand, upon activation, the Smad complex
an associate with a repressor (or corepressor) to
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185TRANSCRIPTIONAL REPRESSION OF EBV LATENT PROMOTER Qpdown-regulate the transcription. To date, several core-
pressors including TGT-interacting factor (TGIF) (Wot-
ton et al., 1999) have been identified. In the course of
etermining Qp regulation in BL cells, we found Qp
as repressed through the Smad4-binding element
SBE) located at the region between 249 and 245 of
p in response to TGF-b treatment. The Qp repression
was caused by the TGF-b-induced association of the
FIG. 1. Schematic representation of the Qp-containing reporter co
construct and its mutants. pGL2B-50m contained mutations (59-GTCTG
deletion mutant, which did not contain SBE. pGL2-Basic is the vect
orresponds to 62415 on the EBV genome of B95-8 strain. (B) Qp-conta
romoter activity was determined by the luciferase activity. pGL2-Basi
as measured by dividing the luciferase activity of each construct with
tandard deviations (SD) are shown by vertical bars.mad3/Smad4 complex with TGIF, a transcription
orepressor.RESULTS
GF-b effector protein Smad4 is identified as a Qp-
interacting protein
To determine the transcription factors that may regu-
late EBNA 1 promoter Qp, we first identified the shortest
promoter sequence of Qp that possesses a promoter
activity. Qp constructs (Fig. 1A) containing various
s and their activities in type 1 BL cells. (A) Qp-containing promoter
to 59-ATGTAGTC-39) in the SBE of Qp. pGL2B-37 was generated as a
rol. The transcription initiation site of Qp is marked as “11”, which
porter gene constructs were transfected into Rael and WW2 cells. The
sed as the negative control plasmid. Relative activity (fold activation)
pGL2B-37. Data were the average of six independent experiments. Thenstruct
GTC-39
or cont
ining re
c was ulengths of a previously identified 125-bp region (Tsai et
al., 1995) were introduced into two BL cell lines, Rael and
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indicates the yeast cells harboring both plasmid pLacZ-5SBE and the
vector control pGAD10. YB-5SBE/Smad4 indicates the yeast cells har-
186 LIANG ET AL.WW2. As shown in Fig. 1B, pGL2B-50 possessed a pro-
moter activity, which was at least 20 times higher than
the basal activity of pGL2B-37 in Rael cells. In addition,
pGL2B-90 and pGL2B-125 showed at least 100-fold
higher activity. A similar, but more obvious, effect was
observed in WW2 cells, in which pGL2B-50 showed
;150-fold higher activity than pGL2B-37, and pGL2B-90
and pGL2B-125, more than 1000-fold higher activity.
Thus, five copies of the sequence between 250 and 237
were used as the bait in yeast one-hybrid screen. From
47 transformants grown on SD/Ura2/Leu2 plates, three
clones showed positive reactions. DNA sequence anal-
ysis revealed that one of three clones contained an
insert whose sequence was identical to nt 1134 to
11427 of Smad4, an effector in TGF-b signal transduc-
ion. This cDNA clone was designated as pGAD/Smad4.
he binding specificity of pGAD/Smad4 was measured
y b-galactosidase activity assay in the yeast one-hybrid
ystem. Yeast cells (YB-5SBE/Smad4) harboring both
LacZ-5SBE and pGAD/Smad4 showed an activity that
as 22-fold higher than that of the parental yeast cells
YM4271), yeast cells (YB-5SBE) harboring pLacZ-5SBE
lone, or yeast cells (YB-5SBE/pGAD10) harboring both
LacZ-5SBE and pGAD10 vector (Fig. 2A). Smad4 is a
NA-binding protein, which recognizes the SBE site
Zawel et al., 1998). Sequence analysis of the 250 to 237
egion of Qp reveals a potential SBE site between 249
nd 245. Therefore, identification of Smad4 binding to
p suggests the function of TGF-b in regulation of EBNA
1 gene expression.
To test whether endogenous Smad4 recognized the
potential SBE site of Qp, the sequence between 254 and
240 of Qp was used as the probe in the electrophoretic
mobility shift assay (EMSA). As shown in Fig. 2B, using
nuclear extracts from TGF-b-treated Rael cells, two com-
lexes were formed. Both complexes were affected by
nlabeled probe, whereas only Complex I was com-
letely competed off by the 200 3 CAGA box, a Smad4-
boring both the reporter plasmid pLacZ-5SBE and the Smad4 cDNA
clone pGAD10/Smad4. The fold activation was determined as de-
scribed under Materials and Methods. (B) Binding of SBE of Qp with the
endogenous and ecotopically expressed Smad4. TGF-b-treated Rael
cell extracts were reacted with 59-end-labeled oligonucleotide (254 to
240 of Qp). For the supershift experiment, the anti-Smad4 antibody or
anti-ATF-2 antibody (as a negative control) was used. For competition
assay, the unlabeled probe or CAGA sequence (which is a Smad4
consensus-binding sequence) was used as the competitor. (C) For
binding of SBE of Qp with ecotopically expressed Smad4, 293 cells
were infected with adenovirus carrying a Flag-tagged Smad4 gene and
then treated with TGF-b. Nuclear extracts isolated from treated cells
were incubated with 59-end-labeled oligonucleotide (254 to 240 of
Qp). For the supershift experiment, the anti-Flag antibody or anti-ATF-2
antibody (as a negative control) was used, respectively. For competition
assay, the unlabeled CAGA sequence or NF-kB motif was used as the
competitor. The products were analyzed on 4% polyacrylamide gel.FIG. 2. Association of Smad4 with Qp determined by yeast one-
ybrid screen and as analyzed by electrophoretic mobility shift assay
EMSA). (A) The sequence between 250 and 237 (59-TGTCTG-
GTCGCTAG-39) relative to the transcription initiation site of Qp was
used as the bait in a yeast one-hybrid screen. The interaction of Smad4
and Qp was examined by b-galactosidase activity in the yeast one-
hybrid system. YM4271 is the parental yeast strain. YB-5SBE indicates
the yeast cells harboring the LacZ reporter plasmid pLacZ-5SBE, which
contains five copies of the 250 to 237 region of Qp. YB-5SBE/pGAD10These results are representative of at least three independent experi-
ments.
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187TRANSCRIPTIONAL REPRESSION OF EBV LATENT PROMOTER Qpbinding site. Furthermore, an anti-Smad4 antibody super-
shifted and reduced the intensity of Complex I. On the
other hand, anti-ATF2 antibody (as a negative control)
had no effect on either complex. A similar pattern was
detected, but less obviously, when nuclear extracts were
isolated from Rael cells without TGF-b treatment (data
not shown). To further confirm the interaction of Smad4
and Qp, the Qp probe was incubated with the nuclear
extract isolated from 293 cells, which was infected with
a recombinant adenovirus carrying the Flag-tagged
Smad4 gene. As shown in Fig. 2C, only one complex was
detected, which was competed off by the unlabeled
probe and the CAGA box, but not by the NF-kB-binding
FIG. 3. TGF-b represses EBNA 1 gene expression in type 1 BL cells
as isolated from the treated cells at 1, 2, 4, 12, 24, 36, and 48 h, respec
nd EBNA 1 gene-specific primers. The RT-PCR products were then s
he percentage decrease of EBNA 1 transcripts is shown at the bottom
eporter construct pGL2B-50 was electroporated into Rael and WW2 ce
ng/ml, respectively. Relative activity was determined by dividing the luc
oncentrations of TGF-b with that of pGL2B-50 without the TGF-b treatm
ertical bars show the standard deviations (SD).otif. Furthermore, this complex was supershifted by
nti-Flag antibody, but not by anti-ATF-2 antibody. Taken
1
ttogether, these results indicated that Smad4, induced
endogenously or introduced exogenously, interacts with
the SBE site of Qp.
TGF-b represses EBNA 1 gene expression and its
promoter activity in type 1 BL cells
To investigate the effect of TGF-b on Qp, BL cells were
treated with TGF-b and RNA was extracted from cells at
1, 2, 4, 12, 24, 36, and 48 h, respectively, after the treat-
ment. The presence of EBNA 1 transcripts was deter-
mined by RT-PCR and EBNA 1 gene-specific primers. As
shown in Fig. 3A, TGF-b reduced the expression of EBNA
pe 1 BL cells Rael were treated with TGF-b at 1 ng/ml and total RNA
fter the treatment. RT-PCR was carried out with RNA from treated cells
d to Southern blot analysis for detection of EBNA 1 gene expression.
ssion of GAPDH gene is used as the internal control. (B) Qp-containing
pectively. Cells were treated without or with TGF-b at 0.25, 0.5, 1, and
activity from each transfection assay after treatment with the indicated
100%). Data were the average of at least six independent experiments.. (A) Ty
tively, a
ubjecte
. Expre
lls, res
iferasetranscripts in Rael cells by ;30% at 1 h after the
reatment, and by ;50% 12 to 48 h after the treatment.
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188 LIANG ET AL.To test whether TGF-b affects Qp activity, pGL2B-50
was introduced into Rael and WW2 cells, which were
then treated with TGF-b. As shown in Fig. 3B, the Qp
activity was repressed by ;20% upon TGF-b treatment at
0.25 ng/ml, by ;40% at 0.5 ng/ml, and by ;50% at 1
ng/ml or higher concentrations, as compared to the ac-
tivity in the absence of TGF-b in both Rael and WW2
cells. Similar results were detected when pGL2B-125
and pGL2B-90 were examined (data not shown). In this
set of experiments, an almost eightfold activation by
TGF-b treatment at 1 ng/ml was observed for p3TP-Lux
(Keeton et al., 1991), a well-studied TGF-b-inducible re-
porter construct, in both cell lines (data not shown).
Taken together, these results indicated that Qp is spe-
cifically repressed by TGF-b in BL cells.
GIF is involved in TGF-b repression of Qp activity in
ype 1 BL cells
A homeoprotein TGIF has been identified as a Smad2/
mad3-binding protein and functions as a corepressor
or TGF-b-inducible transcription (Wotton et al., 1999). To
determine whether TGIF was involved in TGF-b repres-
ion of Qp activity, Flag-tagged TGIF was cotransfected
ith pGL2B-50 into Rael cells and transfected cells were
hen treated with TGF-b (1 ng/ml). As shown in Fig. 4A,
otransfection of cells with Smad3 and Smad4 showed
n almost 20% reduction of Qp activity, which was further
educed to ;75% after TGF-b treatment. Cotransfection
of Smad3/Smad4 and TGIF-expressing vector resulted in
more than ;40% reduction of Qp activity and ;85%
reduction after treatment with TGF-b. This TGF-b-in-
uced repression was inhibited by cotransfection of a
mad4 dominant-negative mutant. These results sug-
est that TGIF and Smad3/Smad4 cooperatively repress
he Qp activity in response to TGF-b treatment.
Association of Smad3/Smad4 with TGIF was then con-
firmed by the coimmunoprecipitation method. Flag-
tagged TGIF-expressing vector was cotransfected with
Myc-tagged Smad3- and Smad4-expressing vectors into
293 cells, followed by TGF-b treatment. As shown in Fig.
4B, the complex immunoprecipitated by anti-Flag anti-
body (for TGIF) contained Smad3 and Smad4, as de-
tected by the subsequent Western blot analysis using
anti-Myc antibody. Similarly, the anti-Smad4 antibody
was able to immunoprecipitate the Flag-tagged TGIF.
The ecotopic expression of TGIF, Smad3, and Smad4
was confirmed by Western blot analysis of the whole-cell
lysates using anti-Flag and anti-Myc antibody, respec-
tively (Fig. 4B). Results confirmed the physical associa-
tion of TGIF and Smad proteins in this study.
Histone deacetylase (HDAC) is involved in TGF-b-
repressed Qp activity in type 1 BL cellsA recent report showed that the TGF-b-induced inhi-
bition of the TGF-b/activin response element (ARE)-con-aining promoter (A3-Lux) activity results from the recruit-
ent of a histone deacetylase (HDAC) by TGIF (Wotton et
l., 1999). To determine whether HDAC participates in
GF-b repression of Qp activity, Rael cells were trans-
fected with pGL2B-50 and pGL2B-50m, and then treated
with either 1 ng/ml of TGF-b or 1 ng/ml of TGF-b plus 100
g/ml of trichostatin A (TSA), a specific inhibitor for
DAC. Plasmid pGL2B-50 contains 250 to 117 se-
uence of Qp and plasmid pGL2B-50m contains muta-
ions at the SBE site of pGL2B-50. As shown in Fig. 4C,
GL2B-50m showed elevated activity and showed loss of
esponsiveness to TGF-b repression (gray bars) as com-
pared to that of pGL2B-50. Treatment with TSA alone
(data not shown) or combined treatment with TGF-b and
TSA (striped bars) also resulted in the release of Qp
repression. Importantly, the promoter activity of pGL2B-
50m was elevated more than threefold over that of
pGL2B-50 in the presence of TGF-b, and this activity was
ot affected by the addition of TSA. These results sug-
est that HDAC is involved in TGF-b repression of Qp
activity and this repression is mediated through the SBE
site within Qp. Similar results were obtained using WW2
cells (data not shown).
DISCUSSION
EBV is known to infect and immortalize human B cells
into continuously growing LCLs in vitro and is associated
ith many human malignant diseases. Earlier studies
emonstrated that EBV and its gene products can induce
GF-b production and secretion in human cells (Cayrol
and Flemington, 1995). In sera of patients with EBV-
associated BL and NPC, the concentration of TGF-b is
higher than that of healthy individuals (Xu et al., 1999,
2000), thus suggesting a role of this cytokine in the
pathogenesis of EBV-associated diseases. In this study,
we identified a transcription factor Smad4, which binds
the SBE site within Qp. We also found that Smad proteins
cooperated with TGIF to repress the Qp via the SBE site
in type 1 BL cells in response to TGF-b stimulation.
Qp is a latent promoter, selectively used in type 1 BL
cells. Upon TGF-b stimulation, this promoter was re-
pressed through the SBE site. Mutation of the SBE site,
therefore, released the TGF-b-induced repression (Fig.
4C). The SBE site is located within the previously iden-
tified positive element QRE-1. QRE-1 is the potential
binding site of the cellular transcription factor LBP-1,
which shows significant promoter activity in conjunction
with the interferon regulatory factor (IRF) binding site
QRE-2 located between 212 and 12 of Qp (Nonkwelo et
al., 1995, 1997). In this study, we found that pGL2B-50
showed an almost 20-fold higher promoter activity than
that of pGL2B-37. Promoter construct pGL2B-50 contains
both the QRE-1 and the QRE-2 sites, while promoter
construct pGL2B-37 contains only the QRE-2 site. As
discussed above, both QRE-1 and QRE-2 sites are re-
Tured b
ansfect
189TRANSCRIPTIONAL REPRESSION OF EBV LATENT PROMOTER Qpquired for a significant promoter activity. This may ex-
plain the low promoter activity of pGL2B-37 observed in
FIG. 4. Transcriptional repression of Qp by cooperation of TGF-b-indu
and TGIF. Rael cells were cotransfected with pGL2B-50 and 1 mg
GIF-expressing vector, and then treated with or without 1 ng/ml of TG
TGIF with Smad3/Smad4 by immunoprecipitation analysis. Flag-tag
cotransfected into 293 cells. Cells were first immunoprecipitated with an
or first precipitated with anti-Smad4 antibody and then analyzed by Wes
Smad4, and TGIF are indicated by horizontal bars. Lower panel: total c
Flag-TGIF identification and anti-Myc antibody for both Myc-Smad3 an
construct pGL2B-50 and its mutant pGL2B-50m were individually electr
TSA, 1 ng/ml of TGF-b, or both. Relative activity (fold increase) was meas
without any treatment. Results were the average of six independent trthis study (Fig. 1B).
The QRE-2- or IRF-binding site within Qp is also over-lapped with two STAT sites (215 to 26 and 11 to 19 of
Qp), which are important for positive regulation of Qp by
mads and TGIF. (A) Transcriptional repression of Qp by Smad3/Smad4
of the expressing plasmids of Smad3 and Smad4 with or without
e plasmid pcDNA3 was used as the vector control. (B) Interaction of
IF and Myc-tagged Smad3- and Smad4-expressing vectors were
antibody and analyzed by Western blot analysis with anti-Myc antibody,
t analysis with anti-Flag antibody. The bands corresponding to Smad3,
tes were directly subjected to Western blot analysis using anti-Flag for
-Smad4 identification. (C) Effect of TSA and TGF-b on Qp activity. Qp
ed into Rael cells and transfected cells were treated with 100 ng/ml of
y dividing the luciferase activity of each treatment with that of pGL2B-50
ions. Vertical bars show the standard deviations (SD).cible S
each
F-b. Th
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oporatthe JAK/STAT pathway (Chen et al., 1999). However, this
activation can be repressed by Zta, which up-regulates
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190 LIANG ET AL.p53 gene expression, and in turn leads to p53-mediated
interference of JAK/STAT signaling (Chen et al., 1999). It is
also known that Zta expression is activated by TGF-b.
hus, Qp can be negatively regulated through the Zta-
ediated interference of the JAK/STAT signaling path-
ay. Therefore, TGF-b might activate Zta, which, in turn,
epresses Qp through the STAT sites. However, the pro-
oter activity of pGL2B-50 was still repressed by TGF-b
in two EBV-negative BL cell lines, Ramos and Akata(2),
o a level similar to that observed in EBV(1) BL cells
data not shown). This eliminates the possibility that Qp
epression was the result of induction of the Zta protein
y TGF-b. It is also true that p53 is often mutated in BL
ells. Therefore, Qp repression examined in this study
as more likely a direct effect in response to TGF-b.
Physically, the potential IRF- and STAT-binding sites are
near the transcription initiation site of Qp, whereas the
SBE identified in this study is located ;30 nt upstream
from these sites. It is conceivable that TGF-b-induced
Smad4 binding interferes with the LBP-1/IRF interaction
at the transcriptional level and vice versa. This may
suggest that the regulatory actions, either by STAT and
IRF or by LBP-1 and Smad4, are mutually exclusive.
Transcriptional control in eukaryotic cells is involved in
multiple layers of cooperativity (Cayrol and Flemington,
1995). TGF-b-induced transcription regulation is not lim-
ted to interactions only between Smad proteins. Asso-
iation of Smad proteins with different transcriptional
actors may contribute to the opposite effect, either tran-
criptional activation or transcriptional repression. Tran-
criptional repression is often a result of recruitment of
istone deacetylase (HDAC) to transcriptional corepres-
ors such as TGIF (Wotton et al., 1999; this study) by
orming a specific transcription complex. In this study, Qp
epression was caused by recruitment of HDAC to the
mad/TGIF complex. Therefore, this supports a model in
hich TGIF is recruited to TGF-b-targeted promoters
uch as Qp, and functions as an adapter to link Smad to
DAC 1, leading to transcriptional repression. However,
e cannot rule out that other repressors or unidentified
actors may be also involved in this Qp repression. EBNA
is an EBV-encoded oncogene, which plays an impor-
ant role in maintaining the viral episomes in infected
ells. Qp is the key promoter in regulating EBNA 1
xpression in EBV-associated tumors. Down-regulation
f Qp by agents such as Smad4 and transcriptional
orepressors might be a possible therapeutic approach
o eradicate the EBV genome from those tumors.
Recent reports by Xu et al. (1999, 2000) indicated that
he levels of TGF-b in serum samples from patients with
EBV-associated BL and NPC are elevated compared to
those from healthy individuals. Levels of this cytokine
could correlate with the severity of NPC (Xu et al., 1999),
lthough it is not clear whether this is also true for BL
atients. Furthermore, other cytokines may regulate the
BV lytic cycle in addition to TGF-b. It has been reported
a
wefore that TGF-b induces latent EBV to enter into the
lytic cycle (di Renzo et al., 1994). Currently, we are testing
whether the BZLF1 gene, a latent-to-lytic switching gene,
is also regulated by TGF-b at the transcriptional level.
tudy of the regulation of EBV genes by TGF-b will be
important to further understand the role of EBV in the
development of tumors.
MATERIALS AND METHODS
Cell lines
Rael and WW2 are EBV-positive type 1 Burkitt’s lym-
phoma (BL) cell lines. These cells were maintained at
37°C in RPMI 1640 medium containing 15% (v/v) fetal
bovine serum (FBS), 100 mg/ml streptomycin, 100 U/ml
enicillin, and 2 mM L-glutamine. The 293 cells were
aintained in DMEM supplemented with 10% (v/v) FBS,
00 mg/ml streptomycin, and 100 mg/ml penicillin.
NA extraction, RT-PCR, and Southern blot
ybridization
Total RNA was isolated from Rael cells treated with 1
g/ml of TGF-b by using REzol C&T protocol (PROtech
echnology, Taiwan, ROC). A 5-mg sample of total RNA
was heated at 70°C for 10 min and rapidly cooled on ice.
Reverse transcription was carried out in a reaction con-
taining 1 mM of gene-specific 39 primer, 39K 59-CCATT-
TCCAGGTCCTGTA-39 for EBNA 1, 0.125 mM dNTP, 8 units
of avian myeloblastosis virus reverse transcriptase
(AMV-RT; Promega, Madison, WI), and 20 units of RNase
inhibitor (Promega) at 42°C for 1 h. PCR assays were
carried out by adding 10 pmol of 59 primer 59 Qp 59-
GCGTTTCTTGAGCTT-39 for EBNA 1 transcripts and 2.5
units of Taq DNA polymerase (Promega) to one-third of
the reverse transcription reaction mixture (Tsai et al.,
1995). RT-PCR products were separated by electrophore-
sis in 2% agarose gel and then transferred to a nitrocel-
lulose membrane. The membrane was fixed in an XL-
1000 UV CROSSLINKER (Spectronics, Westbury, NY) be-
fore hybridization with [a-32P]dCTP-labeled RT-PCR
roducts. After the hybridization reaction, the mem-
ranes were washed in washing buffer containing 0.23
SC and 0.1% SDS for 30 min before exposure to X-ray
ilms.
east one-hybrid system
Five copies of 250 to 237 (59-TGTCTGGTCGCTAG-39)
f EBV Qp was inserted into the SmaI site of pLacZi and
Hisi-1 (Clontech, Palo Alto, CA) to generate pLacZi-
SBE and pHisi-5SBE. Plasmid pLacZi-5SBE was linear-
zed by NcoI and plasmid pHisi-5SBE was digested with
hoI. The linearized plasmids were transformed into
east YM4271, to establish two stable clones, YB-5SBE
nd YH-5SBE. YH-5SBE yeast strain was transformed
ith the metastasized NPC biopsy cDNA library (2.6 3
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191TRANSCRIPTIONAL REPRESSION OF EBV LATENT PROMOTER Qp106 individual colonies) generated with pGAD10 (custom-
made by Clontech) and then selected on SD/His2/Leu2
plates with 45 mM 3-amino-1,2,4-triazole (3-AT; Sigma, St.
Louis, MO). A total of 47 clones was obtained from the
2.6 3 106 colonies of the cDNA library. YB-5SBE yeast
ells were transformed with the purified plasmid DNA
nd selected on SD/Ura2/Leu2 plates. The clones that
howed positive b-galactosidase (b-gal) activity were
isolated and the plasmid DNAs were purified before
being subjecting to DNA sequence analysis. The b-gal
ctivity was assayed with n-nitrophenyl-b-D-galactopyr-
anoside (ONPG) as the substrate by using the b-galac-
osidase enzyme assay system (Promega).
lasmid construction
Qp-containing reporter plasmids were constructed
s follows. Various regions of the Qp (spanning nts
2291 to 62416 of the EBV genome) were individually
enerated by PCR and then cloned into the pGL2-
asic vector (Promega). Briefly, PCR products for
GL2B-125, -90, -50, -50m, and -37 were generated
y Q3/Fb, Q5(59-GAAATTGGGTGACCACTG-39)/Fb,
4(59-TGTCTGGTCGCTAGATGG-39)/Fb, Q4m(59-TATG-
AGTCGCTAGATGG-39)/Fb, and Q2/Fb, respectively,
nd were inserted into HincII-digested pUC18 (Gibco
RL, Life Technologies, Paisley, UK). The recombinant
lasmids digested with HindIII and BamHI were eluted
nd subcloned into HindIII- and BglII-treated pGL2-
asic (Promega). These reporter plasmids were des-
gnated as pGL2B-125, -90, -50, -50m, and -37, respec-
ively (Fig.1) (Tsai et al., 1995).
The expression vectors of pcDNA3-Flag-Smad3,
mad4, and dominant-negative Smad4 mutant (SmadD4)
ere described previously (Zhang et al., 1997).
The full-length TGIF cDNA was generated by RT-PCR
sing primers TGIF-F (59-AATGAAAGGCAAAGGT-39) and
GIF-R (59-TTAAGCCGTAAGTTTTGCC-39). This RT-PCR
roduct was digested with BglII and EcoRI, and then
loned to the BglII- and EcoRI-digested pFlag-CMV2
Kodak, Rochester, NY). The plasmid was designated as
Flag-TGIF.
The sequences of all the constructs were confirmed by
anger’s dideoxy chain-termination method (Sanger et
l., 1977), using the T7 sequence version 2.0 DNA se-
uencing kit (Amersham Life Science, Buckinghamshire,
K) according to the manufacturer’s protocol.
NA transfection and TGF-b treatment
Reporter plasmids (2.5 mg) and the indicated amounts
of expression plasmids were introduced into Rael and
WW2 cells by electroporation at a capacitance of 960 mF
nd a voltage of 0.22 kV using the Gene Pulser (Bio-Rad,
ichmond, CA). After transfection, cells were harvested
nd lysed in 50 ml of lysis buffer (Promega). The concen-
ration of the cell lysates was measured by using Bio-Rad
o
srotein assay reagent. A 50-mg sample of protein ex-
tracts was used to assay the luciferase activity in an
illuminometer (autolumat model LB953; Berthold, Ger-
many).
For TGF-b treatment, cells were first transfected with
indicated plasmid DNA and cultured in RPMI 1640 sup-
plemented with 0.2% FBS for 12 h, prior to treatment with
1 ng/ml of recombinant human TGF-b 1 (R&D Systems,
Minneapolis, MN) for 24 h. All of the plasmid DNAs were
purified by the cesium chloride/ethidium bromide gradi-
ent centrifugation method.
Western blot analysis and immunoprecipitation
For the Western blot analysis, cells were washed three
times with phosphate-buffered saline (PBS) before being
harvested and lysed in the buffer containing 10 mM
Tris–HCl, pH 7.1, 1 mM phenylmethylsulfonyl fluoride
(PMSF), 1 mM EDTA, and 1% Triton X-100. Cells were
disrupted by sonication, after which the cell debris was
removed by centrifugation at 10,000 g. The supernatants
of the whole-cell lysates were then separated by
NaDodSO4–polyacrylamide gel electrophoresis and then
electrotransferred to nitrocellulose membranes and im-
munoblotted with the indicated antibodies. Anti-Flag an-
tibody (Kodak), anti-Myc antibody, and anti-Smad4 anti-
body (Santa Cruz Biotechnology, Santa Cruz, CA) were
obtained commercially. The blot was then subjected to
the ECL system (Amersham, Arlington Heights, IL) for the
detection of TGIF or Smad3/Smad4 proteins.
Coimmunoprecipitation of Smads and TGIF was per-
formed as previously described by Wotton et al. (1999).
The immunoprecipitates were analyzed by SDS–PAGE,
followed by the Western blot analysis as described
above.
Electrophoretic mobility shift assay
The double-stranded oligonucleotide containing two
copies of the 254 to 240 sequence of Qp promoter was
used as the probe in the electrophoretic mobility shift
assay (EMSA). In brief, the oligonucleotide was labeled
with T4 polynucleotide kinase and [g-32P]ATP. Nuclear
xtracts prepared from either Rael cells or 293 cells
nfected by a recombinant adenovirus carrying Flag-
agged Smad4 (kindly provided by Dr. Kohei Miyazono)
ere incubated with 15,000 cpm of [g-32P]-labeled oligo-
ucleotide for 10 min at room temperature in a buffer
ontaining 0.13 mg/ml poly dI:dC, 4% glycerol, 1 mM
MgCl2, 0.5 mM EDTA, 0.5 mM DTT, 50 mM NaCl, and 10
M Tris–HCl, pH 7.5. For competition assay, a 200-fold
xcess of the individual cold double-stranded oligonu-
leotides was added into the reaction mixture before
ddition of the [g-32P]-labeled probe. After a 30-min in-
ubation at room temperature, the samples were loaded
nto 4% nondenaturing acrylamide gel and electrophore-
is was carried out in 0.53 TBE at 100 V for 2.5–3 h. For
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192 LIANG ET AL.the supershift assay, the reaction mixture was incubated
at 4°C with 4 mg of anti-Smad4 antibody (Santa Cruz
Biotechnology), anti-ATF-2 antibody (Santa Cruz Biotech-
nology), and anti-Flag antibody (Kodak), respectively.
The gel was subsequently dried and exposed to Kodak
BioMax film.
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